Répertoire du corps professoral
Yves Fradet
Médecin clinicien enseignant titulaire
yves.fradet@fmed.ulaval.ca
A novel prebiotic tailored for men combating prostate cancer
Programme: Proof-of-Principle 2025: Microbiome-based interventions
Organisme(s) subventionnaire(s): Weston Family Foundation
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 décembre 2025
au 1 janvier 2028
Gut microbiota biomarkers to personalize treatment of bladder cancer
Programme: Proof-of-Principle 2024: Microbial biomarkers of disease and therapeutic response
Organisme(s) subventionnaire(s): Weston Family Foundation
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 décembre 2024
au 30 avril 2027
Investigation multi-omiques des effets des acides gras oméga-3 et de la sélénonèine sur des organoïdes dérivés de patients atteints de cancer de la prostate.
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 2 juillet 2024
au 30 juillet 2026
Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma
Programme: UpCycle 2.1
Organisme(s) subventionnaire(s): Société de recherche sur le cancer
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 août 2022
au 31 juillet 2026
What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer
Programme: Initiative SCC/IC-IRSC en prévention primaire du cancer
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada, Fondation du cancer du sein du Québec, Société canadienne du cancer
Type de financement: Subvention
Établissement tête: Université Laval
Du 15 janvier 2022
au 31 mars 2026
Targeting sex steroids to improve the response to bladder cancer immunotherapy
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2021
au 30 septembre 2026
Financements des 2 dernières années
Developement of a prostate cancer vaccine
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 20 juillet 2022
au 1 mai 2025
En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers
Programme: Transformational Research
Organisme(s) subventionnaire(s): Weston Family Foundation
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juin 2020
au 30 avril 2024
Encadrements terminés dans les 5 dernières années
Publications des 5 dernières années
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet (London, England), 2025/10. De Santis M, Palou Redorta J, Nishiyama H, Krawczyński M, Seyitkuliev A, Novikov A, Guerrero-Ramos F, Zukov R, Kato M, Kawahara T, Goeman L, POTOMAC Investigators. DOI 10.1016/s0140-6736(25)01897-5
Ex vivo culture to evaluate dynamic changes in the tumor microenvironment following durvalumab treatment 2025/08. Gris T, Shore H, Ménard C, Lacombe L, Fradet V, Pouliot F, Lodde M, Fradet Y, Toren P. DOI 10.21203/rs.3.rs-7180379/v1
Poster Session 9: Oncology–Kidney, Testes, Penile : Sunday, June 29, 2025 • 07:00–08:30 Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2025/06. Bahadori A, Bray G, Chung D, Haramesiw O, Tangri N, Breau R, Basappa N, Mallick R, Pouliot F, Finelli A, Rendon R, Lavallee L, Bansal R, Tanguay S, Weight C.
Poster Session 7: Oncology–Prostate (Part 2) : Sunday, June 29, 2025 • 07:00–08:30 Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2025/06. Kovac E, Khawaja I, Kim D, Gurushankar M, Shah R, Mattes M, Weiss R, Mannas M, Ion-Margineanu A, Deng F, Freudiger C, Lough L, Wysock J, Huang W, Rowe N.
Poster Session 3: Oncology–Bladder : Saturday, June 28, 2025 • 16:00–17:30 Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2025/06. Laaraj J, Racine H, Tourigny R, Lachance G, Koné P, Fadel J, Toren P, Bergeron A, Fradet Y, Robitaille K, Fradet V, Reznik G, Macklin C, Gleave M, Kassouf W.
The Germline and Somatic Origins of Prostate Cancer Heterogeneity. Cancer discovery, 2025/05. Yamaguchi TN, Houlahan KE, Zhu H, Kurganovs N, Livingstone J, Fox NS, Yuan J, Sietsma Penington J, Jung CH, Schwarz T, Jaratlerdsiri W, van Riet J, Boutros PC. DOI 10.1158/2159-8290.cd-23-0882
New insights into gut microbiota-prostate cancer crosstalk. Trends in molecular medicine, 2025/05. Laaraj J, Lachance G, Bergeron A, Fradet Y, Robitaille K, Fradet V. DOI 10.1016/j.molmed.2025.03.015
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative. Cancer cell, 2025/04. Terry Fox Research Institute Marathon of Hope Cancer Centers Network. Electronic address: mmarra@bcgsc.ca, Terry Fox Research Institute Marathon of Hope Cancer Centers Network. DOI 10.1016/j.ccell.2025.03.014
The landscape of N<sup>6</sup>-methyladenosine in localized primary prostate cancer. Nature genetics, 2025/03. Xu X, Zhu H, Hugh-White R, Livingstone J, Eng S, Zeltser N, Wang Y, Pajdzik K, Chen S, Houlahan KE, Luo W, Liu S, Xu X, Sheng M, Guo WY, Arbet J, He HH. DOI 10.1038/s41588-025-02128-y
Feasibility and acceptability of a personalised primary prevention strategy for women and men at high risk of breast and prostate cancer: the 3PC study protocol for a pilot randomised controlled trial. BMJ open, 2025/02. Souli I, Lapointe J, Kinsley-Marlie J, Chiquette J, Dorval M, Diorio C, Lauzier S, Audet-Walsh É, Bilodeau S, Côté M, Brisson C, Charette N, Nabi H. DOI 10.1136/bmjopen-2024-085255
A versatile and efficient method to isolate nuclei from low-input cryopreserved tissues for single-nuclei transcriptomics. Scientific reports, 2025/02. Segovia C, Desrosiers V, Khadangi F, Robitaille K, Armero VS, D'Astous M, Khelifi G, Bergeron A, Hussein S, Richer M, Bossé Y, Fradet Y, Fradet V, Bilodeau S. DOI 10.1038/s41598-025-90070-8
2025 Canadian Urological Association Expert Report: Muscle-invasive bladder cancer. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2025/01. Kulkarni GS, Black PC, Sridhar SS, Zlotta AR, Shayegan B, Rendon RA, Chung P, van der Kwast T, Alimohamed N, Fradet Y, Kokorovic A, Cury FL, McAlpine K. DOI 10.5489/cuaj.9096
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2024/12. Fléchon A, Morales-Barrera R, Powles T, Alva A, Özgüroğlu M, Csöszi T, Loriot Y, Rodriguez-Vida A, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Matsubara N. DOI 10.1158/1078-0432.ccr-23-3518
Association des Urologues du Québec Congrès Annuel 2024 – Résumés : Session scientifique IVendredi 8 novembre 2024 • Friday, November 8, 2024 Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2024/12. Olazabal A, Hussain J, Al-Muhaideb M, Tanguay S, Clark G, Aprikian A, Rompré-Brodeur A, Sanchez-Salas R, Kassouf W, Lee N, Nadeau P, Berjaoui M, Ismail S.
Association des Urologues du Québec Congrès Annuel 2024 - Résumés Session scientifique IVVendredi 8 novembre 2024 • Friday, November 8, 2024. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2024/12. DOI 10.5489/cuaj.9082
Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study. Clinical genitourinary cancer, 2024/11. Powles T, Csőszi T, Loriot Y, Matsubara N, Geczi L, Cheng SY, Fradet Y, Alva A, Oudard S, Vulsteke C, Morales-Barrera R, Fléchon A, Gunduz S, Liu CC, Özgüroğlu M. DOI 10.1016/j.clgc.2024.102261
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study. Prostate cancer and prostatic diseases, 2024/08. Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Tagawa ST, Kilari D, Antonarakis ES. DOI 10.1038/s41391-024-00865-5
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial. European urology, 2024/08. de Wit R, Vaughn DJ, Fradet Y, Fong L, Climent MA, Necchi A, Petrylak DP, Gerritsen WR, Gurney H, Quinn DI, Culine S, Sternberg CN, Bajorin DF, Lee JL. DOI 10.1016/j.eururo.2024.07.015
Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes. Frontiers in immunology, 2024/06. Molina OE, LaRue H, Simonyan D, Hovington H, Vittrant B, Têtu B, Fradet V, Lacombe L, Bergeron A, Fradet Y. DOI 10.3389/fimmu.2024.1372837
The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids. Nature communications, 2024/04. Lachance G, Robitaille K, Laaraj J, Gevariya N, Varin TV, Feldiorean A, Gaignier F, Julien IB, Xu HW, Hallal T, Pelletier JF, Bouslama S, Boufaied N, Fradet V. DOI 10.1038/s41467-024-45332-w
The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression. The Journal of clinical investigation, 2024/04. Lafront C, Germain L, Campolina-Silva GH, Weidmann C, Berthiaume L, Hovington H, Brisson H, Jobin C, Frégeau-Proulx L, Cotau R, Gonthier K, Audet-Walsh É. DOI 10.1172/jci170809
A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation. Communications medicine, 2024/03. Robitaille K, Guertin MH, Jamshidi A, Xu HW, Hovington H, Pelletier JF, Beaudoin L, Gevariya N, Lacombe L, Tiguert R, Caumartin Y, Dujardin T, Fradet V. DOI 10.1038/s43856-024-00456-4
Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2024/02. Garneau CA, Marcotte N, Lacombe L, Fradet Y, Fradet V, Pouliot F, Toren P, Lodde M. DOI 10.5489/cuaj.8341
NS-AUA 2023 Annual Meeting Abstracts – Oncology – Prostate Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2023/10. Panzone J, Wu M, Welch C, Jacob J, Shapiro O, Basnet A, Bratslavsky G, Goldberg H, Panzone J, Wu M, Chandrasekar T, Basnet A, Bratslavsky G, Bruce J.
NS-AUA 2023 Annual Meeting Abstracts – Oncology – Bladder, Renal, Testes Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2023/10. Gaba F, Gallagher K, Bhatt N, Clement K, Zimmermann E, Khadhouri S, Kulkarni M, Anbarasan T, Ng A, Light A, Asif A, Chan V, Nathan A, Rossi S, Jacobs B.
Effects of omega-3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double-blind placebo-controlled randomized trial. Cancer medicine, 2023/10. Savard J, Moussa H, Pelletier JF, Julien P, Lacombe L, Tiguert R, Caumartin Y, Dujardin T, Toren P, Pouliot F, Lodde M, Fradet Y, Robitaille K, Fradet V. DOI 10.1002/cam4.6598
Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer. Molecular oncology, 2023/07. Gonthier K, Weidmann C, Berthiaume L, Jobin C, Lacouture A, Lafront C, Harvey M, Neveu B, Loehr J, Bergeron A, Fradet Y, Lacombe L, Riopel J, Audet-Walsh É. DOI 10.1002/1878-0261.13441
High infiltration of CD209<sup>+</sup> dendritic cells and CD163<sup>+</sup> macrophages in the peritumor area of prostate cancer is predictive of late adverse outcomes. Frontiers in immunology, 2023/06. Molina OE, LaRue H, Simonyan D, Hovington H, Têtu B, Fradet V, Lacombe L, Toren P, Bergeron A, Fradet Y. DOI 10.3389/fimmu.2023.1205266
CUA 2023 Annual Meeting Abstracts - Poster Session 9: Oncology - Prostate (Part 2) Sunday, June 25, 2023 • 7:00-8:30. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2023/06. DOI 10.5489/cuaj.8417
CUA 2023 Annual Meeting Abstracts - Poster Session 7: Oncology - Bladder Sunday, June 25, 2023 • 7:00-8:30. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2023/06. DOI 10.5489/cuaj.8415
Leukocytic Infiltration of Intraductal Carcinoma of the Prostate: An Exploratory Study. Cancers, 2023/04. Diop MK, Molina OE, Birlea M, LaRue H, Hovington H, Têtu B, Lacombe L, Bergeron A, Fradet Y, Trudel D. DOI 10.3390/cancers15082217
Supplementary Data from Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials 2023/03/31. Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas. DOI 10.1158/1078-0432.22487295
Supplementary Data from Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials 2023/03/31. Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas. DOI 10.1158/1078-0432.22487295.v1
Data from Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials 2023/03/31. Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas. DOI 10.1158/1078-0432.c.6532491
Data from Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials 2023/03/31. Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas. DOI 10.1158/1078-0432.c.6532491.v1
Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA) Nutrients, 2023/03/11. Hanane Moussa, Karine Robitaille, Jean-François Pelletier, Roxane Tourigny, Yves Fradet, Louis Lacombe, Paul Toren, Michele Lodde, Rabi Tiguert, Thierry Dujardin, Yves Caumartin, Thierry Duchesne, Pierre Julien, Josée Savard, Caroline Diorio, Vincent Fradet. DOI 10.3390/nu15061369
Canadian Bladder Cancer Forum 2023 Meeting Abstracts - Poster Presentations. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2023/03. DOI 10.5489/cuaj.8351
Canadian Bladder Cancer Forum 2023 Meeting Abstracts - Podium Presentations. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2023/03. DOI 10.5489/cuaj.8349
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 2022/12. Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Necchi A, Petrylak DP, O'Donnell PH. DOI 10.1016/j.annonc.2022.11.012
Association des Urologues du Québec Congrès Annuel 2022 - Résumés. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022/12. DOI 10.5489/cuaj.8204
UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways. Cancer letters, 2022/11. Lacombe L, Hovington H, Brisson H, Mehdi S, Beillevaire D, Émond JP, Wagner A, Villeneuve L, Simonyan D, Ouellet V, Barrès V, Latour M, Aprikian A, Lévesque E. DOI 10.1016/j.canlet.2022.215994
Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancer. Urologic oncology, 2022/10. Fadel J, Simonyan D, Fradet V, Lodde M, Lacombe L, Fradet Y, Toren P. DOI 10.1016/j.urolonc.2022.09.024
Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment. European urology open science, 2022/07. Besançon M, Gris T, Joncas FH, Picard V, Bergeron A, Fradet Y, Toren P. DOI 10.1016/j.euros.2022.06.007
CUA 2022 Annual Meeting Abstracts - Poster Session 9: Oncology - Prostate Sunday, June 26, 2022 • 07:30-09:00. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022/06. DOI 10.5489/cuaj.7931
CUA 2022 Annual Meeting Abstracts - Poster Session 7: Oncology - Bladder Sunday, June 26, 2022 • 07:30-09:00. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022/06. DOI 10.5489/cuaj.7929
Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians' perspective. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022/05. Turcotte B, Bélanger L, Blais AS, Blouin AC, Bolduc S, Bolduc-Mokhtar A, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Pouliot F. DOI 10.5489/cuaj.7819
Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion. Molecular metabolism, 2022/05. Frégeau-Proulx L, Lacouture A, Berthiaume L, Weidmann C, Harvey M, Gonthier K, Pelletier JF, Neveu B, Jobin C, Bastien D, Bergeron A, Fradet Y, Audet-Walsh É. DOI 10.1016/j.molmet.2022.101516
Sex steroid modulation of macrophages within the prostate tumor microenvironment. American journal of clinical and experimental urology, 2022/04. Berrehail Z, Boibessot C, Gris T, Joncas FH, Gaignier F, Guillemette C, Lacombe L, Fradet Y, Toren P.
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022/03. Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, Powles T, Plimack ER, Bajorin DF, Grivas P. DOI 10.1158/1078-0432.ccr-21-3089
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. The Lancet. Oncology, 2022/02. Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, GALAHAD investigators. DOI 10.1016/s1470-2045(21)00757-9
Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. Clinical and translational medicine, 2022/01. Boibessot C, Molina O, Lachance G, Tav C, Champagne A, Neveu B, Pelletier JF, Pouliot F, Fradet V, Bilodeau S, Fradet Y, Bergeron A, Toren P. DOI 10.1002/ctm2.581
Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer. Asian journal of andrology, 2022/01. Kourbanhoussen K, Joncas FH, D Wallis CJ, Hovington H, Dagenais F, Fradet Y, Guillemette C, Lacombe L, Toren P. DOI 10.4103/aja.aja_58_21
A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota. Cancer discovery, 2022/01. Messaoudene M, Pidgeon R, Richard C, Ponce M, Diop K, Benlaifaoui M, Nolin-Lapalme A, Cauchois F, Malo J, Belkaid W, Isnard S, Fradet Y, Dridi L, Routy B. DOI 10.1158/2159-8290.cd-21-0808
Identification of Morphologic Criteria Associated with Biochemical Recurrence in Intraductal Carcinoma of the Prostate. Cancers, 2021/12. Diop MK, Albadine R, Kougioumoutzakis A, Delvoye N, Hovington H, Bergeron A, Fradet Y, Saad F, Trudel D. DOI 10.3390/cancers13246243
Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy. Clinical nutrition ESPEN, 2021/12. Fradet S, Pelletier JF, Singbo N, Lacombe L, Toren P, Lodde M, Dujardin T, Tiguert R, Fradet Y, Robitaille K, Fradet V. DOI 10.1016/j.clnesp.2021.12.011
Résumés AUQ 2021. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021/11. DOI 10.5489/cuaj.7674
Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. Journal of biomedical optics, 2021/11. Plante A, Dallaire F, Grosset AA, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Leblond F. DOI 10.1117/1.jbo.26.11.116501
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021/10. Otis-Chapados S, Goulet CR, Dubois G, Lavallée É, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F. DOI 10.5489/cuaj.7107
Northeastern Section of the American Urological Association 73rd Annual Meeting Abstracts. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021/09. DOI 10.5489/cuaj.7599
Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA. International journal of molecular sciences, 2021/09. Lambert M, Benmoussa A, Diallo I, Ouellet-Boutin K, Dorval V, Majeau N, Joly-Beauparlant C, Droit A, Bergeron A, Têtu B, Fradet Y, Pouliot F, Provost P. DOI 10.3390/ijms22189757
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. The Lancet. Oncology, 2021/05. Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, KEYNOTE-361 Investigators. DOI 10.1016/s1470-2045(21)00152-2
Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity. Molecular cancer research : MCR, 2020/12. Gevariya N, Lachance G, Robitaille K, Joly Beauparlant C, Beaudoin L, Fournier É, Fradet Y, Droit A, Julien P, Marette A, Bergeron A, Fradet V. DOI 10.1158/1541-7786.mcr-20-0316
Immune-focused multi-omics analysis of prostate cancer: leukocyte Ig-Like receptors are associated with disease progression. Oncoimmunology, 2020/12. Vittrant B, Bergeron A, Molina OE, Leclercq M, Légaré XP, Hovington H, Picard V, Martin-Magniette ML, Livingstone J, Boutros PC, Collins C, Fradet Y, Droit A. DOI 10.1080/2162402x.2020.1851950
Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth. Prostaglandins, leukotrienes, and essential fatty acids, 2020/11. Bilodeau JF, Gevariya N, Larose J, Robitaille K, Roy J, Oger C, Galano JM, Bergeron A, Durand T, Fradet Y, Julien P, Fradet V. DOI 10.1016/j.plefa.2020.102215
Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer. Frontiers in genetics, 2020/11. Vittrant B, Leclercq M, Martin-Magniette ML, Collins C, Bergeron A, Fradet Y, Droit A. DOI 10.3389/fgene.2020.550894
Building a Canadian Translational Bladder Cancer Research Network. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020/10. Koti M, Berman DM, Siemens DR, Lange D, Wang E, Toren P, Eigl BJ, Hardy C, Purves R, Fradet V, Fradet Y, Mansure J, Kassouf W, Black PC, Canadian Bladder Cancer Research Network. DOI 10.5489/cuaj.6887
A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020/10. Turcotte B, Paquet S, Blais AS, Blouin AC, Bolduc S, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Fradet Y, Lacombe L, Pouliot F. DOI 10.5489/cuaj.6862
Northeastern Section of the AUA 72nd Annual Meeting Abstracts Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020/09.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Oncology, 2020/09. Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, DANUBE study investigators. DOI 10.1016/s1470-2045(20)30541-6
Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. PLoS medicine, 2020/08. Grosset AA, Dallaire F, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Trudel D. DOI 10.1371/journal.pmed.1003281
Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival. World journal of urology, 2020/07. Toren P, Brisson H, Simonyan D, Hovington H, Lacombe L, Bergeron A, Fradet Y. DOI 10.1007/s00345-020-03358-x
Message from our President Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020/06. Zorn K, Bhojani N, Elterman D, Goldenberg S, So A, Paterson R, Desai M, Roehrborn R, Kaplan S, Gilling P, Berto F, Wang Z, Bjazevic J, Filler G, Romao R.
Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. British journal of cancer, 2020/02. Lévesque E, Labriet A, Hovington H, Allain ÉP, Melo-Garcia L, Rouleau M, Brisson H, Turcotte V, Caron P, Villeneuve L, Leclercq M, Droit A, Guillemette C. DOI 10.1038/s41416-020-0749-2
Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study. The Journal of urology, 2020/01. Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Pinthus J. DOI 10.1097/ju.0000000000000714
Les informations contenues dans cette page sont extraites de différents systèmes experts de l’Université Laval. Si vous constatez une erreur ou avez des questions quant aux données affichées, communiquez avec nous en écrivant à l’adresse repertoire-corps-professoral@ulaval.ca. Nous nous assurerons de rediriger votre demande à la bonne personne.